Flag of the European Union EU Clinical Trials Register Help

Clinical trials for breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,852 result(s) found for: breast cancer. Displaying page 11 of 93.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2016-001930-93 Sponsor Protocol Number: GC-627-04 Start Date*: 2017-01-13
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage II-IV breast cancer in the adjuvant or metastatic setting and are scheduled to undergo chemotherapy. This is a profilaxis ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-011079-57 Sponsor Protocol Number: BICG26UMCG-NIRF Start Date*: 2009-05-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of Indocyanine Green (ICG) enhanced Near-InfraRed Fluorescence (NIRF) Imaging for Intra-Operative Sentinel Lymph Node (SLN) detection in Breast Surgery.
    Medical condition: Women above the age of 21 with core biopsy or cytology proven breast cancer stage I and II, eligible for lumpectomy and sentinel lymph node procedure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006194 Breast cancer NOS stage I LLT
    9.1 10006195 Breast cancer NOS stage II LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003217-32 Sponsor Protocol Number: 0006 Start Date*: 2005-11-08
    Sponsor Name:AZIENDA USL DI FORLI
    Full Title: PHASE-II STUDY TO EVALUATE ACTIVITY OF DEXRAZOXANE CARDIOXANE IN ORDER TO PREVENT CARDIAC TOXICITY IN PATIENTS WITH BREAST CANCER AND TREATED WITH ANTHRACYCLINE
    Medical condition: To evaluate activity of Dexrazoxane in order to prevent cardiac toxicity in patients with breast cancer and treated with anthracycline
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057654 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005267-21 Sponsor Protocol Number: IEO 222/604 Start Date*: 2005-04-04
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A RANDOMIZED PHASE II PREVENTION TRIAL IN SUBJECTS AT HIGH RISK FOR HORMONE NON RESPONSIVE BREAST CANCER
    Medical condition: PREVENTION TRIAL IN SUBJECTS AT HIGH RISK FOR HORMONE NON-RESPONSIVE BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057654 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004018-42 Sponsor Protocol Number: FARM5K3MEE Start Date*: 2006-09-15
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients ...
    Medical condition: adjuvant hormono-therapy in breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006279 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000898-68 Sponsor Protocol Number: 2013/VCC/0008 Start Date*: 2014-01-24
    Sponsor Name:Velindre NHS Trust
    Full Title: A phase 1b/2 randomised placebo controlled trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor.
    Medical condition: Estrogen receptor positive advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-003839-30 Sponsor Protocol Number: D081CC00006 Start Date*: 2014-06-16
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germl...
    Medical condition: Adjuvant breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) AT (Trial now transitioned) IS (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001806-17 Sponsor Protocol Number: AS1402-C-201 Start Date*: 2008-11-17
    Sponsor Name:Antisoma Research Limited
    Full Title: A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination with Letrozole as First Line Treatment in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer.
    Medical condition: Locally Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006412-29 Sponsor Protocol Number: 3144A1-203-WW Start Date*: 2007-10-18
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
    Medical condition: Metastatic breast cancer remains incurable and represents an area of unmet medical need globally. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) activat...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003399-36 Sponsor Protocol Number: MK-4214-008 Start Date*: 2011-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubi...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002556-17 Sponsor Protocol Number: SAKK22/10/UC-0140/1207 Start Date*: 2013-02-04
    Sponsor Name:UNICANCER
    Full Title: A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic brea...
    Medical condition: HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Gender: Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-018188-29 Sponsor Protocol Number: Calendula study Start Date*: 2010-08-06
    Sponsor Name:Dept of Oncology
    Full Title: Randomised blinded trial of Calendula Officinalis compared with aqueos cream for the prevention of acute skin toxicity in relation to radiotherapy for breast cancer
    Medical condition: Patients operated for breast cancer who undergo postoperative adjuvant radiotherapy will be offered to participate in this randomized trial with the aim to reduce the risk of severe radiation skin ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006199 Breast cancer stage I LLT
    12.1 10006200 Breast cancer stage II LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004489-17 Sponsor Protocol Number: IEOS733612 Start Date*: 2013-08-02
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: WAVE: Weekly nab-paclitaxel (Abraxane®) Versus Epirubicin in women with early breast cancer who are elderly or unfit for a 3-weekly polychemotherapy regimen: a Phase II Randomized Trial evaluating ...
    Medical condition: early breast cancer in elderly patients or patients who are unfit for a polychemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005021-30 Sponsor Protocol Number: FARM5P8YFC Start Date*: 2007-10-31
    Sponsor Name:REGIONE LOMBARDIA - DIREZIONE GENERALE SANITA'
    Full Title: TOP TRIAL. A RANDOMISED PHASE III CLINICAL TRIAL OF TRASTUZUMAB (HERCEPTIN) OPTIMIZATION IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER OVEREXPRESSING HER2 AFTER A FIRST LINE CHE...
    Medical condition: Women with locally advanced or metastatic breast cancer over expressing HER2 who have been previously treated with a first line chemotherapy plus trastuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024481-22 Sponsor Protocol Number: EP06-302 Start Date*: 2012-01-17
    Sponsor Name:Sandoz GmbH
    Full Title: A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemothe...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-000810-72 Sponsor Protocol Number: PREDIXLumB Start Date*: 2014-12-05
    Sponsor Name:Karolinska University Hospital
    Full Title: PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation with metastatic nodes or young patients. Part of a set of...
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006191 Breast cancer male NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001467-20 Sponsor Protocol Number: COBC Start Date*: 2017-08-19
    Sponsor Name:Dept. of Oncology, Karolinska university hospital
    Full Title: Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-...
    Medical condition: Women with newly diagnosed breast cancer who are expected to receive neo-adjuvant or adjuvant therapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020806 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000509-29 Sponsor Protocol Number: BO25734/TDM4997g Start Date*: 2011-12-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of trastuzumab emtansine compared with treatment of physician’s choice in patients with HER2-positive metasta...
    Medical condition: HER2-Positive Metastatic Breast Cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) SK (Completed) BE (Completed) CZ (Completed) HU (Completed) NO (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005000-13 Sponsor Protocol Number: EMR200027-051 Start Date*: 2007-03-30
    Sponsor Name:Merck KGaA
    Full Title: Randomized Phase II trial with cetuximab and cisplatin in the treatment of ER negative, PgR negative, HER2 negative metastatic breast carcinoma (“basal-like”)
    Medical condition: Metastatic breast cancer PR-negative, ER-negative and HER-2 negative
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) BE (Completed) ES (Completed) AT (Completed) PT (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002860-25 Sponsor Protocol Number: ML19944 Start Date*: 2006-09-27
    Sponsor Name:Roche Hungary Ltd.
    Full Title: A multicenter randomized phase II trial to compare trastuzumab (Herceptin®) continuation or discontinuation in combination with 2nd-line chemotherapies after progression on a 1st-line chemotherapy ...
    Medical condition: Metastacic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) EE (Completed) LT (Completed) SK (Completed) LV (Prematurely Ended) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 07:03:59 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA